B-Cell Depletion in Glomerular Diseases: Not Always as Safe as We May Think
{{output}}
B-cell depletion with the chimeric anti-CD20 monoclonal antibody rituximab has revolutionized the treatment of glomerular diseases. Obinutuzumab, a type II glycoengineered anti-CD20 humanized monoclonal antibody, is increasingly being employed as an alternativ... ...
